Oncolytics Biotech Presents New Data at ASCO Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2026
0mins
Source: Newsfilter
- Clinical Trial Data Presentation: Oncolytics Biotech will present translational data from the GOBLET and AWARE-1 trials at the 2026 ASCO Annual Meeting, further validating the potential of its immunotherapy pelareorep in treating difficult cancers, likely attracting investor interest.
- Mechanism of Immune Response: The research indicates that pelareorep enhances immune responses against KRAS-mutant tumors by expanding pre-existing tumor-reactive immune cells rather than introducing new antigens, potentially providing new insights for future treatment strategies.
- Efficacy Metrics Improvement: In pancreatic cancer studies, the observed expansion of antiviral T cells correlated with reductions in tumor volume post-treatment, demonstrating pelareorep's ability to activate immune responses within the tumor microenvironment, which may improve patient outcomes.
- Strategic Partnerships and Development: Oncolytics is actively pursuing strategic partnerships to accelerate the development of pelareorep, particularly in colorectal and pancreatic cancers where the FDA has granted Fast Track designation, indicating the company's focus on market opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONCY
Wall Street analysts forecast ONCY stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.935
Low
3.00
Averages
5.50
High
10.00
Current: 0.935
Low
3.00
Averages
5.50
High
10.00
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oncolytics Biotech Presents New Data at ASCO Meeting
- Clinical Trial Data Presentation: Oncolytics Biotech will present translational data from the GOBLET and AWARE-1 trials at the 2026 ASCO Annual Meeting, further validating the potential of its immunotherapy pelareorep in treating difficult cancers, likely attracting investor interest.
- Mechanism of Immune Response: The research indicates that pelareorep enhances immune responses against KRAS-mutant tumors by expanding pre-existing tumor-reactive immune cells rather than introducing new antigens, potentially providing new insights for future treatment strategies.
- Efficacy Metrics Improvement: In pancreatic cancer studies, the observed expansion of antiviral T cells correlated with reductions in tumor volume post-treatment, demonstrating pelareorep's ability to activate immune responses within the tumor microenvironment, which may improve patient outcomes.
- Strategic Partnerships and Development: Oncolytics is actively pursuing strategic partnerships to accelerate the development of pelareorep, particularly in colorectal and pancreatic cancers where the FDA has granted Fast Track designation, indicating the company's focus on market opportunities.
See More
GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors
- Trial Launch: On May 14, 2026, GT Biopharma announced that the first patient has been dosed in the Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in treating historically resistant solid tumors.
- Innovative Dosing Method: GTB-5550 is the first TriKE® molecule tested with subcutaneous dosing, administered for five consecutive days in the abdominal area during each four-week cycle, which is expected to enhance patient compliance and reduce treatment-related side effects.
- Broad Tumor Type Coverage: The trial is designed as a basket study encompassing seven solid tumor types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancers, indicating the potential applicability of GTB-5550 across multiple difficult-to-treat tumors.
- Strong Market Demand: With prostate and pancreatic cancers historically unresponsive to standard immunotherapies, GTB-5550 is poised to address this significant unmet medical need, enhancing the company's competitiveness in the rapidly evolving immuno-oncology market.
See More
Oncolytics Biotech Aligns with FDA on Pivotal Study Design for Pelareorep
- Clinical Trial Alignment: Oncolytics Biotech has reached an agreement with the FDA on the design of a pivotal clinical study to support the approval of pelareorep for patients with unresectable metastatic squamous cell carcinoma of the anal canal, indicating the company's proactive progress in developing new therapies.
- Significant Patient Need: Over 10,000 patients are affected by SCAC annually in the U.S., and with no FDA-approved treatment options available after first-line chemotherapy or checkpoint inhibitor therapy, the market potential for pelareorep is substantial.
- Enhanced Efficacy: In a recent study, the combination of pelareorep with a checkpoint inhibitor achieved a median duration of response of 15.5 months compared to 9.5 months with the current standard of care, demonstrating its effectiveness in treating SCAC.
- Strategic Partnership Opportunities: Oncolytics plans to incorporate FDA feedback into the final protocol, with a randomized controlled trial expected to apply for both accelerated and full approval at different points in time, further advancing its strategic development in cancer immunotherapy.
See More
ONCOLYTICS BIOTECH INC - CONFIRMS FDA ALIGNMENT FOR KEY ANAL CANCER TRIAL - SEC FILING
Announcement of Collaboration: Oncolytics Biotech Inc. has announced a strategic alignment with the FDA regarding a pivotal cancer study.
Focus on Cancer Research: The collaboration aims to enhance the development and evaluation of innovative cancer therapies.
See More
Oncolytics Schedules FDA Meeting for Pelareorep Development
- FDA Meeting Scheduled: Oncolytics Biotech has scheduled a Type C meeting with the FDA on April 16, 2026, to discuss the registrational development path for its lead candidate Pelareorep in anal cancer, marking a significant advancement in the oncology immunotherapy sector.
- Clinical Study Design: The meeting will focus on designing a single-arm pivotal study enrolling approximately 60 to 70 patients, primarily evaluating the objective response rate of Pelareorep in combination with a checkpoint inhibitor for patients receiving second-line and later therapy for squamous cell anal carcinoma.
- Early Study Results: In Cohort 4 of the GOBLET study, the combination achieved an approximate 30% objective response rate with a median duration of response of 17 months in late-line patients, indicating its potential in treatment.
- Market Outlook: With approximately 54,000 cases of anal cancer globally each year, the anal cancer market is expected to double from $1.15 billion in 2025 to $2.3 billion by 2035, highlighting the significant commercial value of Oncolytics' development in this area.
See More
Oncolytics Schedules FDA Meeting to Discuss Anal Cancer Development Path
- FDA Meeting Scheduled: Oncolytics Biotech has scheduled a Type C meeting with the FDA on April 16, 2026, to discuss the registration development path for its immunotherapy pelareorep in anal cancer, marking a significant advancement in the company's efforts in this area.
- Clinical Trial Design: The meeting will focus on evaluating a single-arm pivotal study of pelareorep in combination with a checkpoint inhibitor, with plans to enroll approximately 60 to 70 patients and an objective response rate (ORR) as the primary endpoint to support potential full approval.
- Significant Clinical Efficacy: In Cohort 4 of the GOBLET study, the combination of pelareorep and checkpoint inhibitors achieved an ORR of approximately 30%, with a median duration of response of 17 months in late-line patients, significantly outperforming the real-world ORR of 10-14% and median duration of 9.5 months.
- Market Potential: With approximately 54,000 cases of anal cancer diagnosed globally each year, the anal cancer market is projected to double from $1.15 billion in 2025 to $2.3 billion by 2035, indicating substantial commercial opportunities in this sector.
See More
Oncolytics Biotech Presents New Data at ASCO Meeting
- Clinical Trial Data Presentation: Oncolytics Biotech will present translational data from the GOBLET and AWARE-1 trials at the 2026 ASCO Annual Meeting, further validating the potential of its immunotherapy pelareorep in treating difficult cancers, likely attracting investor interest.
- Mechanism of Immune Response: The research indicates that pelareorep enhances immune responses against KRAS-mutant tumors by expanding pre-existing tumor-reactive immune cells rather than introducing new antigens, potentially providing new insights for future treatment strategies.
- Efficacy Metrics Improvement: In pancreatic cancer studies, the observed expansion of antiviral T cells correlated with reductions in tumor volume post-treatment, demonstrating pelareorep's ability to activate immune responses within the tumor microenvironment, which may improve patient outcomes.
- Strategic Partnerships and Development: Oncolytics is actively pursuing strategic partnerships to accelerate the development of pelareorep, particularly in colorectal and pancreatic cancers where the FDA has granted Fast Track designation, indicating the company's focus on market opportunities.
See More
GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors
- Trial Launch: On May 14, 2026, GT Biopharma announced that the first patient has been dosed in the Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in treating historically resistant solid tumors.
- Innovative Dosing Method: GTB-5550 is the first TriKE® molecule tested with subcutaneous dosing, administered for five consecutive days in the abdominal area during each four-week cycle, which is expected to enhance patient compliance and reduce treatment-related side effects.
- Broad Tumor Type Coverage: The trial is designed as a basket study encompassing seven solid tumor types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancers, indicating the potential applicability of GTB-5550 across multiple difficult-to-treat tumors.
- Strong Market Demand: With prostate and pancreatic cancers historically unresponsive to standard immunotherapies, GTB-5550 is poised to address this significant unmet medical need, enhancing the company's competitiveness in the rapidly evolving immuno-oncology market.
See More
Oncolytics Biotech Aligns with FDA on Pivotal Study Design for Pelareorep
- Clinical Trial Alignment: Oncolytics Biotech has reached an agreement with the FDA on the design of a pivotal clinical study to support the approval of pelareorep for patients with unresectable metastatic squamous cell carcinoma of the anal canal, indicating the company's proactive progress in developing new therapies.
- Significant Patient Need: Over 10,000 patients are affected by SCAC annually in the U.S., and with no FDA-approved treatment options available after first-line chemotherapy or checkpoint inhibitor therapy, the market potential for pelareorep is substantial.
- Enhanced Efficacy: In a recent study, the combination of pelareorep with a checkpoint inhibitor achieved a median duration of response of 15.5 months compared to 9.5 months with the current standard of care, demonstrating its effectiveness in treating SCAC.
- Strategic Partnership Opportunities: Oncolytics plans to incorporate FDA feedback into the final protocol, with a randomized controlled trial expected to apply for both accelerated and full approval at different points in time, further advancing its strategic development in cancer immunotherapy.
See More
ONCOLYTICS BIOTECH INC - CONFIRMS FDA ALIGNMENT FOR KEY ANAL CANCER TRIAL - SEC FILING
Announcement of Collaboration: Oncolytics Biotech Inc. has announced a strategic alignment with the FDA regarding a pivotal cancer study.
Focus on Cancer Research: The collaboration aims to enhance the development and evaluation of innovative cancer therapies.
See More
Oncolytics Schedules FDA Meeting for Pelareorep Development
- FDA Meeting Scheduled: Oncolytics Biotech has scheduled a Type C meeting with the FDA on April 16, 2026, to discuss the registrational development path for its lead candidate Pelareorep in anal cancer, marking a significant advancement in the oncology immunotherapy sector.
- Clinical Study Design: The meeting will focus on designing a single-arm pivotal study enrolling approximately 60 to 70 patients, primarily evaluating the objective response rate of Pelareorep in combination with a checkpoint inhibitor for patients receiving second-line and later therapy for squamous cell anal carcinoma.
- Early Study Results: In Cohort 4 of the GOBLET study, the combination achieved an approximate 30% objective response rate with a median duration of response of 17 months in late-line patients, indicating its potential in treatment.
- Market Outlook: With approximately 54,000 cases of anal cancer globally each year, the anal cancer market is expected to double from $1.15 billion in 2025 to $2.3 billion by 2035, highlighting the significant commercial value of Oncolytics' development in this area.
See More
Oncolytics Schedules FDA Meeting to Discuss Anal Cancer Development Path
- FDA Meeting Scheduled: Oncolytics Biotech has scheduled a Type C meeting with the FDA on April 16, 2026, to discuss the registration development path for its immunotherapy pelareorep in anal cancer, marking a significant advancement in the company's efforts in this area.
- Clinical Trial Design: The meeting will focus on evaluating a single-arm pivotal study of pelareorep in combination with a checkpoint inhibitor, with plans to enroll approximately 60 to 70 patients and an objective response rate (ORR) as the primary endpoint to support potential full approval.
- Significant Clinical Efficacy: In Cohort 4 of the GOBLET study, the combination of pelareorep and checkpoint inhibitors achieved an ORR of approximately 30%, with a median duration of response of 17 months in late-line patients, significantly outperforming the real-world ORR of 10-14% and median duration of 9.5 months.
- Market Potential: With approximately 54,000 cases of anal cancer diagnosed globally each year, the anal cancer market is projected to double from $1.15 billion in 2025 to $2.3 billion by 2035, indicating substantial commercial opportunities in this sector.
See More
